Subscribe: Market Wire - Pharmaceuticals and Biotech: Drugs
http://img.marketwire.com/rss/mwPBDR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  announces  clinical  company  health  jan  january  marketwired jan  marketwired january  marketwired  otc pink  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Drugs

Marketwired - Drugs



Marketwired - Drugs



Last Build Date: Mon, 23 Jan 2017 17:23:43 EST

Copyright: Copyright: (C) Marketwired
 



Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call

Mon, 23 Jan 2017 16:05:00 EST

MENLO PARK, CA--(Marketwired - Jan 23, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report preliminary fourth quarter and full year 2016 financial results and provide 2017 revenue guidance and a corporate update on January 30, 2017. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).




mCig Announces 5 Million Reduction in Shares Outstanding

Mon, 23 Jan 2017 16:00:00 EST

HENDERSON, NV--(Marketwired - Jan 23, 2017) -  mCig Inc. (OTCQB: MCIG), a diversified company servicing the legal cannabis, hemp, and CBD markets, announced today that it has begun the process of cancelling 5 million shares of its common stock. 




C.R. Bard, Medikit Lead Japan Vascular Access Market Fueled by Switch from Central Venous to Peripherally Inserted Central Catheters

Mon, 23 Jan 2017 13:24:55 EST

The increasing prevalence of diseases and conditions that require long-term vascular access is fueling the increased use of vascular access devices and is expected to be a driving factor in the Japanese market




Advantis Corp. Developing Rosin Press for Home Use

Mon, 23 Jan 2017 09:26:00 EST

NEWPORT BEACH, CA--(Marketwired - Jan 23, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is currently developing a rosin press designed for home use. The company is adding to its current line up of rosin presses, and is in negotiations to have a well known personality in the cannabis industry represent the Advantis products.




PHZIO Telehealth Marketing Campaign

Mon, 23 Jan 2017 09:00:00 EST

CULVER CITY, CA--(Marketwired - Jan 23, 2017) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first telehealth company for physical therapy to offer insurance reimbursable remotely monitored physical therapy (PT) treatments. The Company has begun direct marketing telephone and email campaigns to multi-clinical PT practices throughout the state of California. The Company has also launched procative marketing campaigns to nationwide PT's on LinkedIn and Facebook. The Company also successfully held its initial webinar last week. Please see the following link to view this webinar: https://wnarchives.s3.amazonaws.com/45426582/62c11c14-baa2-4ad7-b8cd-521b38fd3542/archive.mp4. We also recently updated our PHZIO website that is available at: https://www.phzio.com




GeoVax Announces Initiation of HIV Human Clinical Trial

Mon, 23 Jan 2017 09:00:00 EST

ATLANTA, GA--(Marketwired - Jan 23, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today the initiation of the next human clinical trial of GeoVax's preventive HIV vaccine, GOVX-B11. The Phase 1 trial (designated HVTN 114) is being conducted by the HIV Vaccine Trials Network (HVTN) and is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).




EnWave Signs Commercial Royalty-Bearing License with Van Dyk Specialty Products Ltd., Receives Purchase Order

Mon, 23 Jan 2017 09:00:00 EST

VANCOUVER, BC--(Marketwired - January 23, 2017) - EnWave Corporation (TSX VENTURE: ENW) (FRANKFURT: E4U) ("EnWave", or the "Company") announced today that it has signed a Commercial Royalty-Bearing License (the "License") with Van Dyk Specialty Products Ltd. ("Van Dyk"), a major Canadian producer of wild blueberry products. Van Dyk also submitted a purchase order for EnWave to deliver a large-scale 60kW Radiant Energy Vacuum ("REVT") machine.




The Life Sciences Report Examines the Inclusion of Sorrento Therapeutics on Streetwise Reports' 2017 Small-Cap Biotech Watchlist

Mon, 23 Jan 2017 09:00:00 EST

SAN FRANCISCO, CA--(Marketwired - January 23, 2017) - The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11.




Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome

Mon, 23 Jan 2017 09:00:00 EST

LOS ANGELES, CA--(Marketwired - Jan 23, 2017) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it is collaborating with the newly-established Food for Health Center at the University of Nebraska ("NU") to study the role of the microbiome and RP-G28 in metabolic syndrome.




GB Sciences Resets: Exclusive Executive Interview with CFN Media

Mon, 23 Jan 2017 09:00:00 EST

SEATTLE, WA--(Marketwired - Jan 23, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article and interview discussing recent developments and the path forward for GB Sciences Inc. (OTCQB: GBLX).




Kalytera Therapeutics, Inc. Announces Private Placement

Mon, 23 Jan 2017 08:42:54 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 23, 2017) -




Tetra BioPharma Announces it Has Entered into a Clinical Research Partnership with Sante Cannabis, Quebec's Leading Medical Cannabis Institution

Mon, 23 Jan 2017 08:40:39 EST

OTTAWA, ONTARIO--(Marketwired - Jan. 23, 2017) - PhytoPain Pharma Inc. ("PPP"), a subsidiary of Tetra Bio-Pharma Inc. ("TetraBio" or the "Company" or "TBP") (CSE:TBP)(CSE:TBP.CN) is pleased to announce that it has entered into a clinical research partnership with Santé Cannabis. Under the partnership, Santé Cannabis will be working with PPP to develop the late phase clinical trial protocols that will be used to obtain substantial evidence of the safety and efficacy of PPP001 required for a new prescription drug approval from Health Canada and the USA Food and Drug Administration ("FDA"). These ground-breaking trials seek to receive the first approval for a Canadian-manufactured cannabis-based prescription medication.




Progressive Care: PharmCo Signs 340B Agreement with Community AIDS Network

Mon, 23 Jan 2017 08:30:00 EST

MIAMI, FL--(Marketwired - January 23, 2017) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, announces the execution of an agreement to be a 340B prescription provider for Community AIDS Network.




Easton Pharmaceuticals Signs Letter Of Intent to Acquire Major Vaporizer and e-Liquids Manufacturer iBliss Inc.

Mon, 23 Jan 2017 08:00:00 EST

iBliss's Current Sales Are In the Millions Of Dollars and Are Projected To Quickly Reach and Surpass $15,000,000 in Sales With Healthy Profit Margins in Excess of 40%




Cronos Calls Shareholder Meeting to Formalize Name Change

Mon, 23 Jan 2017 08:00:00 EST

TORONTO, ON--(Marketwired - January 23, 2017) - PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos" or the "Company"), seeks shareholder approval to formally change its name to "Cronos Group Inc." following the corporate rebranding announced on October 6, 2016.




Helix BioPharma Corp. Announces CAR-T Poster Presentation at AACR Annual Meeting 2017 in Washington, DC

Mon, 23 Jan 2017 07:45:00 EST

CAR-T cell harboring a camelid single domain antibody as a targeting agent to kill tumours expressing VEGFR2




GoodRx and Triplefin Partner to Provide Co-Pay Assistance Programs to Consumers

Mon, 23 Jan 2017 07:00:00 EST

SANTA MONICA, CA and CINCINNATI, OH--(Marketwired - January 23, 2017) - GoodRx, America's #1 source for prescription prices and savings, and Triplefin, an industry leader in providing pharmaceutical hub services, including patient access and adherence solutions, today announced an innovative partnership to provide manufacturer prescription co-pay savings coupons to GoodRx's five million unique monthly visitors.




Introducing the Inaugural Medical Capital Innovation Competition

Mon, 23 Jan 2017 07:00:00 EST

Gathering Innovators with Big Ideas in Big Healthcare Data




Medigus Receives First Purchase Order for MUSE in Italy

Mon, 23 Jan 2017 07:00:00 EST

OMER, ISRAEL--(Marketwired - Jan 23, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that it received the first purchase order (PO) for the MUSET system in Italy from INNOVAMEDICA S.p.A, a privately-owned distributor of minimally invasive medical devices, in accordance with their existing distribution agreement.




The Life Sciences Report Asks If It Is Time to Go Long on BrainStorm Cell Therapeutics

Mon, 23 Jan 2017 07:00:00 EST

SAN FRANCISCO, CA--(Marketwired - January 23, 2017) - Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases.




Omni Health, Inc. Reports $1.0M Net Income and a $1.6M Consolidated Proforma Income for 1st Quarter of Fiscal Year 2017

Mon, 23 Jan 2017 07:00:00 EST

MIAMI, FL--(Marketwired - Jan 23, 2017) - Omni Health, Inc. (OTC PINK: OMHE), a pharmaceutical company, filed today its first quarter results for fiscal year 2017, ending July 31, 2016. OMHE recorded a $1.08M net income, which incorporated Malecon Pharmacy, Inc., a wholly owned subsidiary of OMHE as of June 22, 2016. In addition to the results, and in accordance with ASC 805-10-50, the Company provided the results of net income of the combined results of the Company's consolidated operations with the acquisition as if the acquisition had been completed as of the beginning of the reporting period. As such, the proforma results was $1.6M Net Income. The Company recognized a one-time sale of discontinue operations of VitaCig to mCig, Inc. (OTC: MCIG), in the amount of $1.1M leaving a $500K adjusted proforma net income for the consolidated quarter.




Fraser Institute Media Advisory: How could stronger patent protections for pharmaceuticals boost the Canadian economy? New study coming Tuesday, Jan. 24

Mon, 23 Jan 2017 05:00:00 EST

VANCOUVER, BC--(Marketwired - January 23, 2017) - On Tuesday, Jan. 24, the Fraser Institute will release a new study examining intellectual property rights and pharmaceuticals in Canada.




Diet Doc's New Sermorelin GHRP-2 Stimulates Weight Loss for Men and Women

Mon, 23 Jan 2017 01:00:00 EST

PHOENIX, AZ--(Marketwired - January 23, 2017) - Much safer than the controversial hCG diet, our new Sermorelin with an added peptide, GHRP-2 is a muscle enhancer and weight loss aid for both men and women who are looking to gain and preserve muscle mass, speed up their metabolisms and slow down the aging process. Sermorelin is a growth hormone that is known to promote the healthy function of the body's main human Growth Hormone (hGH). hGH has often be used for hormone replacement therapy treatments, but not without a range of adverse and often debilitating side effects. Sermorelin however, is considered to be a much safer alternative since it functions by stimulating the natural release of hGH within the body.




Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference

Sun, 22 Jan 2017 19:00:07 EST

SYDNEY, AUSTRALIA--(Marketwired - Jan 22, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces that the submission titled "TACTI-mel, Two ACTive Immunotherapies in Melanoma: Combination of IMP321 (LAG-3Ig) with an Anti-PD-1 Antagonist in a Phase I Trial" has been accepted for a presentation at the 2nd Annual Cancer Immunotherapy Conference, part of 24th International Molecular Medicine Tri-Conference, in San Francisco, California, between February 20 - 22, 2017.




Ubiquitech Software Corp. Announces Earnings Release Date and First Shareholder Conference Call

Fri, 20 Jan 2017 12:36:54 EST

DENVER, CO--(Marketwired - Jan 20, 2017) - Ubiquitech Software Corp. (OTC PINK: UBQU) is pleased to announce that it will be releasing earnings results on Thursday, January 26th. Following the close of market the company will also be holding an investor conference call at 4:30PM EST.




NutraFuels, Inc. (NTFU) Appoints Mr. Daniel Slane to the Company's Advisory Board and Engages the Services of The Slane Company LLC. to Spearhead the Company's Expansion into Several Key International Markets

Fri, 20 Jan 2017 09:16:48 EST

COCONUT CREEK, FL--(Marketwired - January 20, 2017) - NutraFuels, Inc. ("NutraFuels" or "NTFU") (OTC PINK: NTFU) today announced that the company has engaged the services of Mr. Daniel Slane of The Slane Company LLC., to spearhead and advise on various expansion opportunities into several key international markets including Europe, Asia, India and Africa.




Servier Appoints MaSTherCell for the Development of its CAR-T Cell Therapy Manufacturing Platform

Fri, 20 Jan 2017 09:00:00 EST

GERMANTOWN, MD--(Marketwired - Jan 20, 2017) -   Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its wholly-owned subsidiary, MaSTherCell S.A., specializing in the delivery of optimized process industrialization capacities to cell therapy organizations, has signed a master service agreement with Servier for the development of a manufacturing platform for allogeneic cell therapies. Under the master service agreement, MaSTherCell is developing a CAR-T cell therapy manufacturing platform, which will enable industrial and commercial manufacturing of Servier's cell therapy products. This is a critical step in the development of these products for later stage clinical trials.




Progressive Care Beats Expectations with over $18 Million in 2016 Revenues

Fri, 20 Jan 2017 08:30:00 EST

MIAMI, FL--(Marketwired - January 20, 2017) - Progressive Care, Inc. (OTC PINK: RXMD), through its subsidiary PharmCo, LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, announces record breaking 2016.




Rennova Health's Pharmacogenomics Subsidiary Granted Patent

Fri, 20 Jan 2017 08:30:00 EST

WEST PALM BEACH, FL--(Marketwired - January 20, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announced today that its Genomas, Inc. pharmacogenomics subsidiary has been granted a Patent by the US Patent and Trademark Office.




New Xtalks Webinar on Clinical Evaluation Reports (CERs): Global Benefits and The Impact of MEDDEV Updates to Manufacturers

Fri, 20 Jan 2017 07:30:00 EST

During a live broadcast, the speaker will examine the requirements listed in MEDDEV 2.7/1 revision. 4, discuss notable changes from MEDDEV 2.7/1 revision 3, while focusing on the global benefits of the Clinical Evaluation Report for your product's path to market.




Dr. Nishant Rao Finds Evidence of Low-Reliability in hCG Drops

Fri, 20 Jan 2017 01:00:00 EST

PHOENIX, AZ--(Marketwired - January 20, 2017) - Many dieters are taking hCG (drops, tablets and injections) in addition to their Weight Watchers or other calorie counting diet programs this season to burn fat more rapidly. hCG (human chorionic gonadotropin) is the placental glycoprotein hormone whose levels rise during pregnancy. Used since the 1950s as a hormone treatment in conjunction with a very low calorie diet, hCG is purported to signal to the brain where excess fat is stored and enables its release from fatty areas of the body. Dr. Nishant Rao, Medical Director of the nationally recognized weight loss program, Diet Doc, has researched the effectiveness of hCG in its different forms and has found that injections of hCG drops may offer inconsistent results when compared to injections or tablets. "hCG drops come in two different forms: a prescription version and an over the counter homeopathic version. Both options are far inferior to hCG tablets or injections for the following reasons: the prescription drops are very poorly absorbed even though they are the actual prescription hormone, so most of the liquid ends up mixing with saliva and is swallowed." He continues, "hCG that is swallowed is deactivated and ineffective."




Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer

Thu, 19 Jan 2017 18:07:57 EST

SYDNEY, AUSTRALIA--(Marketwired - Jan 19, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced the first patient has been dosed as part of the enlarged randomised phase of its AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer.




IntelGenx Grants Stock Options

Thu, 19 Jan 2017 16:15:00 EST

SAINT-LAURENT, CANADA--(Marketwired - Jan. 19, 2017) - IntelGenx Technologies Corp. ("IntelGenx", or the "Company") (TSX VENTURE:IGX)(OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire a total of 300,000 common shares under the 2016 Stock Option Plan.




Cronos Applauds German Legalization of Medical Cannabis

Thu, 19 Jan 2017 16:10:41 EST

TORONTO, ON--(Marketwired - January 19, 2017) - PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos" or the "Company"), is pleased to announce that the German parliament has expanded its medical marijuana program. In a landmark bill, members of Germany's parliament voted unanimously to legalize the use of medical marijuana and have implemented a policy that will provide health insurance coverage for patients with an eligible prescription. The medical marijuana program and accompanying health insurance regulations will cover both dried cannabis flower, as well as cannabis extracts.




Newly Created Standards Coordinating Body Seeks to Advance Development and Establishment of Regenerative Medicine Standards

Thu, 19 Jan 2017 15:23:19 EST

Builds upon call for standards development in 21st Century Cures Act




PBMI Releases Second Pharmacy Trends in Accountable Care Organizations Report

Thu, 19 Jan 2017 13:00:00 EST

PLANO, TX--(Marketwired - Jan 19, 2017) -  The Pharmacy Benefit Management Institute released the second edition of its Pharmacy Trends in Accountable Care Organizations Report today, sponsored by Takeda Pharmaceuticals, U.S.A., Inc. This is the industry's only report exclusively dedicated to exploring pharmacy management trends in the commercial, Medicaid, and Medicare ACO space. The report reflects responses from 141 providers representing 8.3 million patients from across the country.




The Alliance for Regenerative Medicine Launches Standards Coordinating Body to Advance Development and Establishment of Industry-Wide Standards

Thu, 19 Jan 2017 12:22:41 EST

Builds upon call for standards development in 21st Century Cures Act




Capha Pharmaceuticals to Focus on Medical Marijuana Industry Under Leadership of Kyle J. Remenda President & COO

Thu, 19 Jan 2017 10:00:00 EST

WEST KELOWNA, BC--(Marketwired - January 19, 2017) - CAPHA PHARMACEUTICALS INC. ("Capha" and/or the "Company") is pleased to announce that the Company will be focusing on the medical marijuana industry under the leadership of Kyle J. Remenda, the Company's recently appointed President & COO.




Somnia Anesthesia Hosts Its CRNA of the Year Contest During CRNA Week

Thu, 19 Jan 2017 10:00:00 EST

Nominations for Somnia's Sixth Annual CRNA of the Year Award Now Open




Amedica Announces Pricing of Public Offering to Raise $4.5 Million

Thu, 19 Jan 2017 09:46:33 EST

SALT LAKE CITY, UT--(Marketwired - Jan 19, 2017) -  Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics, today announced the pricing of an underwritten public offering of common stock and warrants with a public offering price of $0.51 for one share of common stock and 0.45 warrants. Each whole warrant is exercisable for one share of common stock. The Company expects to receive gross proceeds of approximately $4.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted a 45-day option to the underwriters to purchase up to an additional 15% of the shares of common stock plus up to 15% of the warrants; provided that in no event may the aggregate market value of securities sold in the offering, including from the over-allotment option, exceed the limitations set forth in Rule I.B.6 of Form S-3 solely to cover over-allotments, if any.







Vaxil Bio Expands Into Infectious Diseases With First US Patent for MTbuVax(TM)

Thu, 19 Jan 2017 09:30:00 EST

Receives USPTO Notice of Allowance for MTbuVax(TM) Family of Signal Peptide Vaccines and their use in Treating Major Infectious Diseases




Invictus MD Strategies Outlines Vision in Exclusive Interview with CFN

Thu, 19 Jan 2017 09:15:00 EST

SEATTLE, WA--(Marketwired - Jan 19, 2017) -  CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article and interview discussing recent developments and the path forward for Invictus MD Strategies Inc. (CSE: IMH) (OTC PINK: IVITF).




Abattis Explores Diversifying with a Strategic Acquisition -- CFN Media

Thu, 19 Jan 2017 09:15:00 EST

SEATTLE, WA--(Marketwired - Jan 19, 2017) -  CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing Abattis Bioceuticals Corp. (OTC PINK: ATTBF) (CNSX: ATT), a specialty agricultural technology firm focused on the legal cannabis industry. The company recently commissioned an independent valuation on Green Nature Health Care Products Inc. in advance of a potential strategic acquisition. The move would follow the company's international licensing and co-branding agreement signed in November of last year and Green Nature's strong financial performance since then.




AssistRx Acquires Caret(TM), Providing Users with Cutting Edge Technology to Boost Patient Care Management, Adherence, and Compliance

Thu, 19 Jan 2017 09:01:00 EST

ORLANDO, FL--(Marketwired - Jan 19, 2017) -  AssistRx (ARx), the leading enterprise technology platform focused on simplifying the patient journey for specialty and highly-managed medications, today announces its acquisition of Caret, and Caret's Care Management Platform. Caret provides healthcare providers, specialty pharmacies, patients, and payers a best-in-class communication platform powered by actionable data such as point-of-service decision making, care management programs and near real-time updates on patients. ARx plans to integrate these features into the AssistRx Platform, to enhance the patient journey, drive quality-based healthcare, and improve outcomes.




InMed Pharma Appoints Eli Lilly Finance Executive to Board of Directors -- CFN Media

Thu, 19 Jan 2017 09:00:00 EST

SEATTLE, WA--(Marketwired - Jan 19, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing InMed Pharmaceuticals Inc.'s (OTCQB: IMLFF) (CNSX: IN) recent appointment of Martin Bott to its Board of Directors, the company's existing team, and what it means as InMed progresses towards its first clinical trial in INM-750 for the treatment of Epidermolysis Bullosa as well as the rest of its clinical pipeline.




AXIM Biotech Begins CanChew Plus Clinical Trials -- SECFilings.com

Thu, 19 Jan 2017 09:00:00 EST

REDONDO BEACH, CA--(Marketwired - Jan 19, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc.'s (OTCQB: AXIM) recently announced clinical trials evaluating its CanChew Plus® cannabidiol (CBD) gum for the treatment of irritable bowel syndrome (IBS).




Lexaria and NeutriSci Announce Successful Cannabinoid Tablet Development and Positive Results From Initial Human Observational Trials

Thu, 19 Jan 2017 08:00:00 EST

KELOWNA, BC--(Marketwired - January 19, 2017) - Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") and NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX VENTURE: NU) (FRANKFURT: 1N9) are pleased to announce the successful development and initial trial of the industry's first zero-sugar cannabinoid / pterostilbene edible tablet utilizing both NeutriSci's and Lexaria's proprietary and patented technologies.




Golden Leaf to Present on Cannabis Investor Webcast on January 26, 2017

Thu, 19 Jan 2017 08:00:00 EST

TORONTO, ON--(Marketwired - January 19, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, is pleased to announce that it will be a presenting company on the upcoming Cannabis Investor Webcast. The Webcast is scheduled to take place on Thursday, January 26, and GLH is scheduled to present from 2pm ET to 2:45pm ET.




Reliq Health Technologies Announces Development of Mobile App for Cannabis Patients

Thu, 19 Jan 2017 08:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 19, 2017) - Reliq Health Technologies Inc. (TSX VENTURE:RHT)(OTCQB:RQHTF) ("Reliq" or the "Company"), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community-Based Healthcare, is pleased to announce that it has developed a novel mobile application to support patients who have been prescribed medical marijuana.




70% of Global Drug Safety Teams Outsource Case Management Activities

Thu, 19 Jan 2017 07:44:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - January 19, 2017) - Data published by pharmaceutical competitive intelligence firm Cutting Edge Information found that literature services are the most commonly outsourced item among 70% of surveyed pharmacovigilance teams.




Vertical Integration of CRISPR/Cas9 Genome Engineering in Drug Discovery, New Webinar Hosted by Xtalks

Thu, 19 Jan 2017 07:30:00 EST

TORONTO, ON--(Marketwired - January 19, 2017) - Industry expert Dr. Anne-Marie Zuurmond, Associate Director of Genome Engineering, Discovery, Charles River Laboratories will discuss several CRISPR/Cas9 case studies during this webinar covering different aspects of the drug discovery process with an emphasis on the generation of in vitro models for high-throughput screening and the creation of new mouse models of disease.




Nutritional High Announces Inclusion Into U.S. Marijuana Index

Thu, 19 Jan 2017 07:30:00 EST

TORONTO, ONTARIO--(Marketwired - Jan. 19, 2017) - Nutritional High International Inc. (the "Company" or "Nutritional High") (CSE:EAT)(CSE:EAT.CN)(OTCQB:SPLIF)(FRANKFURT:2NU) is pleased to announce that it has been added to the U.S. Marijuana Index.




Moleculin Announces Expanded Scientific Advisory Board

Thu, 19 Jan 2017 07:00:00 EST

HOUSTON, TX--(Marketwired - January 19, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that Drs. Sandra Silberman and Paul Waymack have joined the Company's Scientific Advisory Board (SAB). The Company's current SAB also includes Dr. Waldemar Priebe (Chair) and Dr. Madeleine Duvic.




Two Rivers Properties Begin Rent Revenue

Thu, 19 Jan 2017 07:00:00 EST

Two Rivers to Re-emphasize Development of Water Assets




Optymyze Takes the Gold in Brandon Hall Group's 2016 Excellence in Technology Awards

Thu, 19 Jan 2017 07:00:00 EST

Optymyze Sales Operations is Recognized for Best Advance in Sales Enablement and Performance Tools




Proto Script Pharmaceutical Corp. Building New Partnerships with Independent Practice Associations (IPA)

Thu, 19 Jan 2017 06:00:00 EST

RANCHO CUCAMONGA, CA--(Marketwired - Jan 19, 2017) - Proto Script Pharmaceutical Corp. dba PSP Homecare ("PSP" or the "Company") (OTC PINK: PSCR), a durable medical equipment provider, today provided this update regarding its current business and future expansion plans with Independent Practice Associations.




Diet Doc Offers Safer Weight Loss Alternatives For The hCG Diet Than Starvation-Based Simeons Method

Thu, 19 Jan 2017 01:00:00 EST

PHOENIX, AZ--(Marketwired - January 19, 2017) - The hCG diet has, historically, been controversial because of its application within the Simeons diet. Despite being associated with dramatic weight loss of up to a pound per day, the hCG diet wasn't very well understood until recently. The original hCG diet, or Simeons diet, involved combining low doses of hCG (human chorionic gonadotropin), a hormone produced during pregnancy, with extremely low caloric intake to promote rapid weight loss by burning "abnormal" fat, located in cells and around internal organs. In theory, hCG accumulates in the hypothalamus, sends a signal to areas with excess fat storage, and makes fat loss possible. That original hCG formula, however, is seriously dangerous because it is essentially a starvation diet that caps daily consumption to 500 calories. It leads to harmful side effects like weakness, muscle loss, and hair loss. The Obesity Medicine Association has highlighted the dangers of the hCG-based Simeons method, marking it as unsafe and not recommended.




Targazyme Inc. Receives Additional U.S Patent Award Designed to Improve Cell Therapy Clinical Efficacy Outcomes

Wed, 18 Jan 2017 16:16:23 EST

CARLSBAD, CA--(Marketwired - January 18, 2017) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy, safety and cost of care outcomes for patients undergoing cancer immunotherapy, stem cell transplantation and regenerative medicine, announced today that the United States Patent & Trademark Office has awarded Targazyme, Patent 9,511,095 entitled "Cells Treated by In-Vitro Fucosylation and Methods of Production and Use Thereof".




Amedica Announces Proposed Public Offering of Common Stock and Warrants

Wed, 18 Jan 2017 16:01:00 EST

SALT LAKE CITY, UT--(Marketwired - Jan 18, 2017) - Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The common stock and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). Net proceeds from the offering will be used by Amedica to (1) remain in compliance with the financial covenants in its outstanding Loan and Security Agreement; (2) support working capital needs and other general corporate purposes; (3) fund research and development and commercialization activities of Amedica's product candidates, including the funding of clinical trials Amedica plans to conduct for its product candidates; and (4) continue to build sales, marketing and distribution capabilities for Amedica's silicon nitride technology platform and other products, including the costs of inventory and instruments.




Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico

Wed, 18 Jan 2017 14:50:36 EST

BATON ROUGE, LA--(Marketwired - January 18, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the receipt of acknowledgement and authorization to perform the protocol proposed for the Phase 2/3 clinical trial of ProscaVax from the Department of Urology of the High Specialty Hospital IMSS Siglo XXI ("HSH IMSS") in Mexico. The clinical study is being sponsored by OncBioMune Mexico S.A. de C.V., a joint venture between the Company and its planned acquisition target, Vitel Laboratorios S.A. de C.V., and being conducted at HSH IMSS, which is considered the foremost government hospital in Mexico.




PHZIO Telehealth Webinar Link

Wed, 18 Jan 2017 13:30:36 EST

CULVER CITY, CA--(Marketwired - Jan 18, 2017) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first telehealth company for physical therapy to offer insurance reimbursable remotely monitored physical therapy (PT) treatments. The Company successfully held its initial webinar this morning. Please see the following link to view this webinar: https://wnarchives.s3.amazonaws.com/45426582/62c11c14-baa2-4ad7-b8cd-521b38fd3542/archive.mp4. More information about our telehealth solution is available at our PHZIO.COM website: https://www.phzio.com




Brown Technical Media Corp. Announces Uplist to the QB Tier of the OTC Markets

Wed, 18 Jan 2017 10:30:00 EST

HOUSTON, TX--(Marketwired - Jan 18, 2017) - Brown Technical Media Corp., a division of Panther Biotechnology Inc. (OTCQB: PBYA), an e-commerce company building the first full service training and career advancement brand for the skilled trades, is pleased to announce today that it has been accepted for up listing to the OTCQB effective immediately.




American Green Leverages App Platform

Wed, 18 Jan 2017 10:22:31 EST

Gathers Market Insights for Future Revenue Streams




Premier Biomedical Pain Management Solutions Announces Product Distribution Agreement of Their Superior Pain Relief Products

Wed, 18 Jan 2017 10:15:00 EST

EL PASO, TX--(Marketwired - Jan 18, 2017) - Premier Biomedical, Inc. (OTCQB: BIEI) announced today their newly created joint venture company, Premier Biomedical Pain Management Solutions, LLC (PBPMS) has signed a distribution agreement contract with the Pain Relief & Wellness Strategy Center in Grove City, Pennsylvania to sell and distribute its pain relief products. Initially, the contract will cover pain relief patches and roll-ons, but will expand as new products are introduced.




EAG Laboratories Adds New Capabilities in Dermal Absorption Testing

Wed, 18 Jan 2017 09:00:00 EST

HERCULES, CA--(Marketwired - Jan 18, 2017) - EAG Laboratories, a global scientific services company that provides testing, analytical and characterization services to technology- and life-science-related industries, announced the addition of dermal absorption studies to its suite of GLP-compliant testing services. The company now offers testing outlined in OECD 427 (in vivo studies in rodent models) and OECD 428 (in vitro studies using human and animal skin), which are often performed in parallel to predict dermal absorption in humans (sometimes called "the triple pack" or "parallelogram" approach).




Medical Marijuana Secures Partnership with Key Pharmaceutical Distributor -- CFN Media

Wed, 18 Jan 2017 09:00:00 EST

SEATTLE, WA--(Marketwired - Jan 18, 2017) -  CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering Medical Marijuana Inc.'s (OTC PINK: MJNA) recent groundbreaking agreement with a South American pharmaceutical distributor and how the company aims to capitalize on the market.




Predictive Technology Group, Inc. (PRED) Reaches Key Clinical Milestone in Development of Genetic Tests for Infertility and Endometriosis

Wed, 18 Jan 2017 09:00:00 EST

Development of ARTGuide(R) Test Will Rapidly Accelerate Short-Term Company Growth




Biomerica Announces Second Quarter Financial Results; Sales up Over 22% for the Quarter

Wed, 18 Jan 2017 08:19:00 EST

IRVINE, CA--(Marketwired - January 18, 2017) - Biomerica, Inc. (NASDAQ: BMRA) today reported net sales of $1,432,206 for the three months ended November 30, 2016, compared to $1,165,080 for the same period in the previous year, an increase of 22.9%. Net sales were $2,842,317 for the first six months of fiscal 2017 compared to $2,452,073 for the first six months in fiscal 2016, an increase of 15.9%.




Pharma Compliance Teams Approving Physician Compensation Cap Exceptions

Wed, 18 Jan 2017 08:17:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - January 18, 2017) - Although more pharmaceutical companies have instituted compensation limits as a response to scrutiny over their payments to physicians, there are still exceptions to those rules.




Vinergy Resources/MJ Biopharma Appoint Scientific Advisory Board Chair to Pursue Clinical Testing of Cannabinoids for Therapeutics

Wed, 18 Jan 2017 08:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 18, 2017) - Vinergy Resources Ltd. ("Vinergy" or the "Company") (CSE:VIN)(CSE:VIN.CN) in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce that it has appointed Dr. William Panenka, MD as Chair of the Company's Scientific Advisory Board (SAB). Bringing on the right human capital through strategic hires is an important part of the Company's strategy to develop, test and identify specific cannabinoid isolates for targeted therapeutic purposes.




Upcoming Webinar on Development by Design: Hovione's Approach to Spray Drying Process Development

Wed, 18 Jan 2017 07:30:00 EST

TORONTO, ON--(Marketwired - January 18, 2017) - On Tuesday, January 31, 2017, Xtalks will host a complimentary webinar featuring Márcio Temtem, Associate Director of Particle Design and Formulation Development at Hovione and João Vicente, Team Leader of Particle Engineering and Solubility Enhancement at Hovione, as the keynote speakers.




MediXall Appoints Dr. Pedro A. Sanchez, D.O., to be its First Medical Director

Wed, 18 Jan 2017 07:30:00 EST

FT. LAUDERDALE, FL--(Marketwired - Jan 18, 2017) - MediXall Group, Inc. (OTCQB: MDXL) is pleased to announce the appointment of its first Medical Director, Dr. Pedro A. Sanchez, D.O. Dr. Sanchez is a graduate of Southeastern College of Osteopathic Medicine in Ft. Lauderdale, Florida, and served his residency at Wellington Regional Medical Center in Wellington, Florida. Dr. Sanchez is Board Certified by the American Osteopathic Board of Family Physicians, and has been a successful family practice physician for over 25 years.




Omni Health, Inc. names Andrey Soloviev as New CEO

Wed, 18 Jan 2017 07:25:04 EST

MIAMI, FL--(Marketwired - Jan 18, 2017) -  Omni Health, Inc., (OTC PINK: OMHE), a pharmaceutical company, announced today the Board of Directors has selected Andrey Soloviev as its new Chief Executive Officer. Mr. Soloviev will take over, effective immediately, for interim CEO, Michael Hawkins, who shall remain the company's interim CFO. 




Adam Equipment Introduces Approved Version of Highland(R) Portable Precision Balance

Wed, 18 Jan 2017 03:44:00 EST

EC Type/OIML-approved portable precision balances legal for trade use




Prima BioMed to Maintain NASDAQ Listing

Wed, 18 Jan 2017 02:02:58 EST

SYDNEY, AUSTRALIA--(Marketwired - Jan 18, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company's American Depositary Shares have maintained a closing bid price of US$1.00 per share or greater for 10 consecutive business days from 28 December 2016 to 11 January 2017. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule") and the Company's American Depositary Shares will remain listed on the NASDAQ Global Market.




Diet Doc Reveals The Crucial, But Often Ignored, Role of Blood Sugar in Effective Weight Loss

Wed, 18 Jan 2017 01:00:00 EST

SANTA FE, NM--(Marketwired - January 18, 2017) - For nearly 50 years, obesity rates have been rapidly rising in the U.S. Over a third of all American adults are now considered "obese" even though 77% of Americans are "trying to eat healthier" and 19% are 'actively dieting.' There is certainly no shortage of dietary programs available, as the weight loss market has grown to over $64 billion. With the surplus of fatty foods and sugar in the American diet, however, obesity rates may not decrease anytime soon. Well-regulated blood sugar, for instance, has no negative effect on one's health or ability to lose weight. When someone consumes more sugar than their body can handle for a period of time, however, they start developing problems related to their body's ability to process sugar. According to Dr. Nishant Rao, resident medical expert at Diet Doc, a nationally recognized weight loss center, this leads the 'fasting glucose' (the amount of sugar present in the blood stream away from eating) to go up and stay up. "Elevations in blood sugar not only can eventually lead to diabetes, but are also correlated with heart disease and obesity. This can start to happen because they body can only process or handle a certain amount of glucose before the body has to do something else with it and that is generally to store it as fat." The problem can even worsen if there is an issue of insulin resistance, where there is even less of the sugar to be processed normally, leading much more of it to end up as fat tissue.[...]



B. Braun Medical and Overlook Medical Center's Collaborative Peripheral IV Catheter Educational Outcomes Research Results Published in the Journal of the Society for Simulation in Healthcare

Tue, 17 Jan 2017 15:20:00 EST

BETHLEHEM, PA--(Marketwired - Jan 17, 2017) - B. Braun Medical Inc. collaborated with Overlook Medical Center, part of New Jersey-based Atlantic Health System, to conduct a randomized trial assessing the impact of B. Braun's proprietary blended, simulation-based educational intervention on staff nurses' peripheral intravenous catheter (PIVC) knowledge, confidence, and procedural skills. The study results showed significant improvements in these areas in a simulated environment.1 The research manuscript was published in the December issue of Simulation in Healthcare.




Minnesota's Manufacturing Job Growth Slows

Tue, 17 Jan 2017 15:01:33 EST

EVANSTON, IL--(Marketwired - January 17, 2017) - Minnesota manufacturing employment inched up for a fifth straight year, though at a far slower rate than reported in previous years, according to the 2017 Minnesota Manufacturers Register®, an industrial database and directory published by Manufacturers' News, Inc. (MNI) Evanston, IL. According to MNI's database of manufacturers, Minnesota added 946 jobs between October 2015 and October 2016, a bump of just a third of one percent.




Ross' Gold(TM) and Rokin To Launch the New Gold Standard in Vape Pens

Tue, 17 Jan 2017 13:11:34 EST

Launch of the Ross Gold Special Edition Cyclone(TM) to Take Place at High Times Business Summit in Los Angeles Jan 19th to 20th 2017




FPS Pharma Changes Name to Capha Pharmaceuticals Inc.

Tue, 17 Jan 2017 11:10:05 EST

Kyle J. Remenda Appointed President & COO




Health Advance Announces the Closing of the Acquisition of Hantian Labs

Tue, 17 Jan 2017 10:45:10 EST

LAS VEGAS, NV--(Marketwired - Jan 17, 2017) -  Health Advance Inc. (the "Company") (OTC PINK: HADV) is pleased to announce that the Company has closed the Share Exchange Agreement ("Agreement") to acquire Hantian Labs Limited, a private UK corporation (Hereinafter referred to as "Hantian"). As a result of the acquisition, Health Advance will also control 99% of JT Hantian LLC representing the revenue arm of Hantian. Pursuant to the Agreement, the Company has issued 18,000,000 common shares of the Company to the shareholders of Hantian Labs representing the purchase price of Hantian. Accordingly, the Company's issued and outstanding number of common shares increased from 26,520,000 shares to 44,520,000 shares. In addition, Company has waived Hantian's undertaking to raise a minimum financing of $250,000 for marketing of Hantian's product line prior to closing.




WorldatWork Announces Recipients of 2017 Seal of Distinction

Tue, 17 Jan 2017 10:22:12 EST

WASHINGTON, DC--(Marketwired - January 17, 2017) - WorldatWork, a nonprofit HR association and compensation authority, is proud to announce that a record 160 organizations have been awarded the prestigious Seal of Distinction. The Seal is a unique mark of excellence designed to identify organizations with a strong total rewards portfolio that delivers a positive workforce experience. All of the 2017 recipients will be recognized during the WorldatWork Total Rewards Conference & Exhibition, May 7-10, in Washington, D.C.




Tufts Clinical and Translational Science Institute and Baim Institute for Clinical Research Announce Partnership

Tue, 17 Jan 2017 10:10:00 EST

Students, Faculty, Researchers, and Patients to Benefit from New Collaboration




CORRECTION - Endexx Corporation

Tue, 17 Jan 2017 09:49:41 EST

CAVE CREEK, AZ--(Marketwired - Jan 17, 2017) - In the news release issued earlier today by Endexx Corporation (OTC PINK: EDXC), we are advised by the company the headline should read, "Endexx Engages Turner, Stone & Company as Auditor and Eilers Law Group to Prepare for Up Listing" rather than "Endexx Engages Turner, Stone & Company as Auditor and Eilers Law Group to Prepare for Up Listin" as originally issued. Complete corrected text follows.




Advantis Corp. Boosts Bottom Line, Reduces Debt

Tue, 17 Jan 2017 09:26:00 EST

NEWPORT BEACH, CA--(Marketwired - Jan 17, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) announced that it has settled into its new commercial space to meet surging demand of Amstercan, rosin presses, and other products. The company has also announced that it has reduced debt by $250,000.




Exclusive Interview with Tetra Bio-Pharma CSO Discussing Task Force Recommendations, DEA -- CFN Media

Tue, 17 Jan 2017 09:15:00 EST

SEATTLE, WA--(Marketwired - Jan 17, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and story covering the effect recent Canadian Cannabis Task Force recommendations and DEA actions could have on Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CSE: TBP) as the company continues development of smokable marijuana as treatment for a variety of conditions.




GeoVax to Collaborate with Georgia State University on Development of Therapeutic Hepatitis B Vaccine

Tue, 17 Jan 2017 09:00:00 EST

Targeting Chronic Hepatitis B Infections Affecting More Than 240 Million People Worldwide




Common Heart Drug Repurposed to Treat Rare Cancer in Europe

Tue, 17 Jan 2017 09:00:00 EST

Orphan Drug Designation Confirms Propranolol's Treatment Benefits




PHZIO Telehealth Clinic Orientation and On-boarding

Tue, 17 Jan 2017 09:00:00 EST

CULVER CITY, CA--(Marketwired - Jan 17, 2017) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first telehealth company for physical therapy to offer insurance reimbursable remotely monitored physical therapy (PT) treatments. The Company is pleased to announce that it has begun clinic orientation and on-boarding of selected PT's at Motion PT Group and our other previously announced PT clinic licensees. More information about our telehealth solution is available at our PHZIO.COM website: https://www.phzio.com




Advanced Proteome Therapeutics Corporation Announces Issuance of U.S. Patent Covering Novel Molecules for the Treatment of Cancer

Tue, 17 Jan 2017 09:00:00 EST

VANCOUVER, BC--(Marketwired - January 17, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce issuance of APC's U.S. Patent Application 14/400,190 titled "Site-Specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer".




Progressive Care: PharmCo Opens Resource Center in Century Village

Tue, 17 Jan 2017 08:30:00 EST

MIAMI, FL--(Marketwired - January 17, 2017) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, announces a new Resource Center for the exclusive use for residents of Century Village of Pembroke Pines, FL.




Critical Outcome Technologies to Be a Panelist and Presenter at Cantech Investment Conference in Toronto

Tue, 17 Jan 2017 08:30:00 EST

LONDON, ON and BOSTON, MA--(Marketwired - January 17, 2017) - Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company") a clinical stage biotechnology company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that it will be a panelist and presenter at the 2017 Cantech Investment Conference on January 18th at the Metro Toronto Convention Centre.




Canada House Provides Revenue Update

Tue, 17 Jan 2017 08:30:00 EST

TORONTO, ONTARIO--(Marketwired - Jan. 17, 2017) - Canada House Wellness Group Inc. (formerly Abba Medix Group Inc.) ("Canada House") or the ("Company") (CSE:CHV)(CSE:CHV.CN) is pleased to provide revenue information regarding the recently completed acquisition of 672800 N.B. Inc. doing business as Marijuana for Trauma ("MFT").




Pharmaceutical Key Account Managers Favor Hospital System Accounts

Tue, 17 Jan 2017 08:17:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - January 17, 2017) - The majority of surveyed pharmaceutical key account manager (KAM) groups are most likely to support hospital system accounts (88%) and regional/local-level government payers (76%), according to recent data published by competitive intelligence provider Cutting Edge Information.




Glue Named Top 20 New York Ad Agency

Tue, 17 Jan 2017 08:00:00 EST

NEW YORK, NY--(Marketwired - Jan 17, 2017) - Glue Advertising was recently recognized as one of the top 20 advertising agencies in New York. Expertise.com ranked just under 2,000 agencies in the city on 25 variables, across 5 categories, and distinguished Glue for its quality of customer service.




MJTV Completes the Spin Off of BullsNBears Holdings, Inc. Eliminating more than $1,000,000 In Debt and Liabilities from MJTV's Books

Tue, 17 Jan 2017 08:00:00 EST

WHIPPANY, NJ--(Marketwired - Jan 17, 2017) - Michael James Enterprises, Inc. (OTCQB: MJTV) is pleased to report that it has eliminated more than $1,000,0000 of debt and liabilities with the spin off of BullsNBears Holdings, Inc. on December 27, 2016.




Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors

Tue, 17 Jan 2017 08:00:00 EST

LOS ANGELES, CA--(Marketwired - Jan 17, 2017) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced it has appointed William Merino, Ph.D., to its Board of Directors. Dr. Merino will occupy a newly-created seat, advising on regulatory, clinical and related strategies.




Endexx Engages Turner, Stone & Company as Auditor and Eilers Law Group to Prepare for Up Listin

Tue, 17 Jan 2017 08:00:00 EST

CAVE CREEK, AZ--(Marketwired - Jan 17, 2017) - Endexx Corporation (OTC PINK: EDXC), a provider of innovative phyto-nutrient based food and nutritional products, today announced that it has engaged Turner, Stone & Company LLP and has initiated audits for its fiscal 2015 and 2016. The audit will bring current Endexx's financials for the past four years. In addition, Eilers Law Group will then file all SEC documents on behalf of Endexx to bring the company to fully audited status and in full compliance with the SEC.




Beyond the Smoke Stacks: Texas Ropes in $4 Billion Pharma-Bio Investment, an Industrial Info News Alert

Tue, 17 Jan 2017 07:30:00 EST

SUGAR LAND, TX--(Marketwired - Jan 17, 2017) - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- When many people hear the word "Texas," it evokes a number of clichés, typically a mélange of cattle, chemical plants, oil and gas drilling, and rodeos. But that sells the state short, for beyond the smoke stacks of the hundreds of the state's chemical processing plants and refineries are a surprising number of life-science manufacturing plants and research centers.